We are a human-scale, international, and independent pharmaceutical group governed by a Foundation. Our unique model makes us proud and, more importantly, enables us to fully serve our mission: "committed to therapeutic progress for the benefit of patients."
As a global leader in cardiology, we aim to become a focused and innovative player in oncology by 2030, targeting hard-to-treat cancers and dedicating more than 70% of our R&D budget to this goal.
Who are we? 22,000 passionate individuals from over 50 nationalities, driven by an entrepreneurial spirit. Every day, we move forward with and for patients, with and for our teams, motivated by the desire to care, to dare, to grow, and to commit to being useful to those in need.
Come and experience and contribute to our commitment #MovedByYou.
We are seeking a senior scientist in drug delivery and non-clinical formulation for our research and development center located at Servier Paris-Saclay Research and Development Institute at Gif-sur-Yvette (91).
As part of the Early Formulation and Drug Profiling (EFDP) team in DMPK, the Senior Scientist will be responsible for leading drug delivery innovation projects, non-clinical formulation activities, and physicochemical characterization to ensure the selection and advancement of drug candidates into development. He or she brings specialized expertise in low-solubility and/or low-permeability molecules optimizing oral bioavailability and in new delivery approaches for modalities such as oligonucleotide and antibody-based therapeutics. He or she plays a pivotal role in evaluating the most suitable drug delivery systems and the developability of compounds to ensure a smooth transition of projects into clinical development.
This position involves planning, executing and supervising experimental work in the laboratory. This is a partially lab-based position with access to technical team or through subcontractors.
He or she also contributes to the development and implementation of new technologies in the laboratory including AI predictions and modeling.
The Senior Scientist works closely with the DMPK teams as well as the in vivo teams (i.e., pharmacology and toxicology), the small-molecule drug design department, the Translational Medicine and CMC departments, and the therapeutic areas to ensure timely delivery to portfolio projects.
Formulation Strategy: Design and oversee formulation strategies - such as lipid systems, solid dispersions, and nanosuspensions - for complex, poorly soluble or poorly permeable molecules) to maximize in vivo exposure and oral bioavailability while ensuring molecular stability.
Developability Assessment: Lead the assessment of the “developability” of NCEs (New Chemical Entities) by analyzing the impact of physicochemical properties on solubility, dissolution, and absorption.
Technical Expertise & Innovation: Identify and implement advanced targeted drug delivery technologies in particular through the blood brain barrier for brain diseases and in vitro tools to characterize permeability and dissolution.
Cross-Functional Collaboration: Serve as an expert point of contact within interdisciplinary project teams (MedChem, DMPK, Nonclinical Safety CMC, etc.) to ensure data alignment and the resolution of complex problems (troubleshooting).
Reporting & Monitoring: Summarize results, draft high-level technical reports, and actively monitor scientific and regulatory developments and technological advancements. Share information (dissemination and follow-up) and communicate work results both internally and externally.
Mentoring: Support the professional development of colleagues (Associate Scientists, technicians) and ensure the transfer of technical expertise.
We are committed to equal opportunities and developing talents in all their diversity. We value both experience and the desire to engage daily in contributing to therapeutic progress for the benefit of patients. If this offer resonates with you, seize this opportunity to meet us!
Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle.
As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D.
Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion.
--
To report a suspected adverse event with a Servier drug, please visit servier.com
